---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-258534"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2022-10-06T23:59:59+00:00"
generated_at: "2026-06-23T05:11:15.301740+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics updates epetraborole development; Phase 1 Japan study supports 500 mg dose; EU orphan designation

## Summary
- Phase 1 study in Japanese volunteers (EBO-103) showed no adverse events, supports once-daily 500 mg dose for Phase 2/3.
- Epetraborole exposures similar across ADH genotypes and consistent with prior Phase 1 study in non-Japanese subjects.
- EU Commission granted orphan medicinal product designation for epetraborole in NTM lung disease.
- Company plans to initially focus clinical development for treatment-refractory MAC lung disease on Japan and the U.S.

## SEC filing metadata
- accession: 0001193125-22-258534
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2022-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312522258534/0001193125-22-258534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312522258534/d383473d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-258534
- JSON: https://secwatch.observer/filing/0001193125-22-258534.json
- Plain text: https://secwatch.observer/filing/0001193125-22-258534.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.